$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Hematology
Hematology
达沙替尼(施达赛)的多少钱
2025-10-19 11:44:20
Check Details
达沙替尼(施达赛)适应症
2025-10-19 11:44:20
Check Details
达沙替尼(施达赛)效果好不好
2025-10-19 11:44:20
Check Details
达沙替尼(施达赛)的价格
2025-10-19 11:44:20
Check Details
达沙替尼(施达赛)效果好吗
2025-10-19 11:44:20
Check Details
达沙替尼(施达赛)的使用说明
2025-10-19 11:44:20
Check Details
达沙替尼(施达赛)效果怎么样
2025-10-19 11:44:20
Check Details
达沙替尼(施达赛)的适应症
2025-10-19 11:44:20
Check Details
新药CC-486延长老年急性髓系白血病平均生存期10个月!
2025-10-19 11:44:20
Check Details
达沙替尼(施达赛)纳入医保了吗
2025-10-19 11:44:20
Check Details
达沙替尼(施达赛)如何购买
2025-10-19 11:44:20
Check Details
达沙替尼(施达赛)的效果如何
2025-10-19 11:44:20
Check Details
1
2
...
515
516
517
518
519
520
521
...
935
936
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Common Adverse Reactions and Clinical Safety Management of Gilteritinib (Xospata)
2
Adverse Reaction Profile and Clinical Safety Management of Idelalisib
3
Clinical Significance of Platelet Recovery During Revumenib (Menin Inhibitor) Therapy
4
A Key Therapeutic Breakthrough Against T315I-Mutant CML
5
Tafasitamab: An Fc-Enhanced CD19-Targeted Immunotherapy for B-Cell Malignancies
6
Tafasitamab and Lenalidomide Combination Therapy Guide
7
Pirtobrutinib (Jaypirca) Medication Guide: Overcoming BTK Resistance & Safety Management
8
Gilteritinib Professional Medication Guide & Dosage Management
9
Pirtobrutinib: A Novel Non-Covalent BTK Inhibitor for Relapsed Hematologic Malignancies
10
Clinical Application and Safety Monitoring of Revumenib (Menin Inhibitor) in Acute Leukemia
11
Ixazomib & Pomalidomide in Multiple Myeloma: Mechanisms & Clinical Insights
12
Plerixafor: Mobilizing Hematopoietic Stem Cells for Autologous Transplantation